<- Go Home
Protagenic Therapeutics, Inc.
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Market Cap
$3.2M
Volume
70.1K
Cash and Equivalents
$1.1M
EBITDA
-$5.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$1.87
52 Week Low
$0.46
Dividend
N/A
Price / Book Value
3.14
Price / Earnings
-0.37
Price / Tangible Book Value
3.14
Enterprise Value
$2.1M
Enterprise Value / EBITDA
-0.41
Operating Income
-$5.3M
Return on Equity
231.87%
Return on Assets
-94.91
Cash and Short Term Investments
$1.1M
Debt
N/A
Equity
$719.0K
Revenue
N/A
Unlevered FCF
-$2.8M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium